Condition (MeSH)
Idiopathic Interstitial Pneumonias
ClinicalTrials.gov lists 28 trials for Idiopathic Interstitial Pneumonias or a narrower condition beneath it. Kyntra Bio has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
27 of the 28 trials are tagged with Idiopathic Interstitial Pneumonias itself; the rest are tagged with a narrower condition beneath it.
When did Idiopathic Interstitial Pneumonias trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 4 |
| 2019 | 4 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 2 |
| 2014 | 2 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Idiopathic Interstitial Pneumonias trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 1 |
| Phase 2 | 8 |
| Phase 3 | 2 |
| Observational | 14 |
How many Idiopathic Interstitial Pneumonias trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 4 |
| Completed | 10 |
| Terminated | 6 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Idiopathic Interstitial Pneumonias trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Kyntra Bio | 3 |
| Bayer | 1 |
| Biogen | 1 |
| Bristol-Myers Squibb | 1 |
| Celgene | 1 |
Showing 5 of 9 sponsors.
Which drugs are being tested for Idiopathic Interstitial Pneumonias? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| FG-3019 | 3 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SC1011 | 1 |
| L01XE31 - Nintedanib | 1 |
| 1% Azithromycin | 1 |
| Bone marrow mesenchymal stem cells | 1 |
| Positron Emission Tomography (PET) | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Idiopathic Interstitial Pneumonias trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Idiopathic pulmonary fibrosis | 147 | 6 |
| Pneumonia | 84 | 7 |
| Acute respiratory failure | 45 | 6 |
| Respiratory failure | 42 | 7 |
| Pulmonary embolism | 19 | 7 |
Showing 5 of 10 adverse events.
Which publications cover Idiopathic Interstitial Pneumonias? (28)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Prognostic prediction for newly diagnosed patients with idiopathic interstitial pneumonia: JIPS Registry (NEJ030). | Respiratory investigation | 2025 | Yes |
| Clinical significance of anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonia: a retrospective observational study. | BMC pulmonary medicine | 2025 | Yes |
| Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis. | BMC pulmonary medicine | 2024 | Yes |
| Design and rationale of the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry. | Respiratory investigation | 2023 | Yes |
| Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. | The European respiratory journal | 2023 | Yes |
Showing 5 of 28 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Idiopathic interstitial pneumonia | 98300 | Exact | Orphadata Science knowledge files, Product 1 |
| Idiopathic interstitial pneumonia | 98300 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence.